The peer-reviewed evidence behind every biomarker we ship. Publications, ongoing studies, and the technology underneath.
The largest long-COVID clinical study to-date, led by UCLH/UCL with 30+ partner organisations. Co-founders Prof. Sir Mike Brady and Dr Rajarshi Banerjee were study team members.
Visit study → Diabetes & cardiovascular riskRecruiting people living with diabetes to evaluate whether MRI of multiple organs can identify adults at higher risk of heart disease.
Learn more → MASH endpoint qualification · cT1 RLSE 2029Used as the imaging biomarker in multiple Phase 2b MASH programmes including with leading sponsors. FDA Letter of Intent in submission positioning LiverMultiScan-cT1 as a Reasonably Likely Surrogate Endpoint (RLSE) for MASH; full approval anticipated from 2029. Most recently flagged by US economic modeling as the most appropriate tool for resmetirom adoption.
Read the analysis →If you lead a research programme that needs quantitative imaging at the core, our science team will get back to you with a structured collaboration brief within five working days.
